Overview
MICROPORT (853)
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People...
- Open
- 6.075
- High
- 6.075
- Low
- 6.075
- Prev. Close
- 6.075
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- 0.00%
- 52wk High
- 14.160
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- 5.830
- HK Mkt Cap
- 11.65B
- Market CapHKD
- 11.65B
- P/ETTM
- 30.85
- P/EDynamic
- 30.85
- P/EStatic
- --
- EPSTTM
- 0.197
- EPSDynamic
- 0.197
- EPSStatic
- --
- BVPS
- 3.98
- P/B
- 1.53
- HK Shares
- 1.92B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.92B
- Min lot size
- 100
- Currency
- HKD
MICROPORT Analyst Rating
View moreForecast & Rating
Nov 11, 2026- Strong buy57.14%
- Buy14.29%
- Hold28.57%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 4
- Buy
- 1
- Hold
- 2
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
MicroPort Scientific halted trading today with zero volume confirmation. Shares are in a pronounced downtrend: down 43.49% year-to-date and 62.68% below the October 2025 peak of HKD 16.28, now hovering near 52-week lows. The trading halt reflects recent management transitions — Jonathan Chen appointed new CEO and executive director with concurrent Board and Committee member disclosures filed. Quarterly financials present a revenue-growth-without-profitability pattern: latest two quarters achieved 18%+ year-over-year revenue increases and subsidiary Endovastec posted 10.26% nine-month growth, yet earnings per share deteriorated into negative HKD -0.37 per quarter, down 50% year-over-year, underscoring profitability challenges. The extended trading suspension suppresses near-term price discovery; both resumption timing and subsequent market reception remain uncertain.
- Nov, 13
MicroPort Scientific halted from trading today with zero volume and turnover. The stock has declined 43.49% year-to-date from its January opening price of HK$10.75 and fallen 62.68% from its 52-week high of HK$16.28 recorded on October 7, 2025, currently trading at HK$6.075 near 52-week lows. The trading suspension reflects investor caution following the appointment of Jonathan W. Chen as CEO and Executive Director on October 28. Financial results show Q4 EPS of -0.3735 HKD, yet net profit swung to profitability with 181.32% year-over-year growth reaching HK$370 million, while revenue grew 18.34% to HK$2.17 billion with a net margin of 17.05%. Subsidiary Endovastec reported 9-month revenue growth of 10.26% to RMB 112 million, indicating operational momentum within the business units. At a PE of 30.85x and market capitalization of HK$1.16 billion, valuation has compressed significantly.
- Nov, 12
MicroPort Scientific (853.HK) remains halted today with no trading activity, as the stock price is frozen at HKD 6.075. The company recently announced the appointment of new CEO Jonathan Chen and filed updated Board and Committee member lists, reflecting ongoing governance issues that have triggered the prolonged trading suspension. From a valuation standpoint, the stock has declined 62.68% from its 52-week high of HKD 16.28 reached in October 2025, and is down 43.49% year-to-date, trading now near its 52-week low of HKD 5.83. The latest quarterly results paint a contradictory picture of the business: operating revenue expanded around 18% year-over-year, yet earnings per share turned sharply negative at HKD -0.3735 (down over 50% year-on-year); meanwhile, net profit surged over 180% year-over-year despite an operating loss, exposing significant structural challenges in the company's operational model.
- Nov, 11
MicroPort Scientific remained halted throughout trading with zero volume and no price movement at HK$6.075. The stock has plummeted 43.49% year-to-date and 62.68% below its October 2025 peak of HK$16.28, compressing market cap to HK$11.648 billion and nearing the 52-week low. However, operating fundamentals have not deteriorated proportionally: latest quarter showed revenue of HK$2.17 billion (up 18% YoY) and net profit of HK$370 million (up 181% YoY) with net margin stable at 17%. Recent developments include the appointment of Jonathan W. Chen as CEO and Executive Director, and subsidiary Endovastec achieving nine-month revenue of RMB 1.12 billion. The trading suspension has eliminated liquidity entirely, with resumption as a critical near-term catalyst.
- Nov, 10
MicroPort Scientific remains halted due to governance issues, leaving the stock with zero trading activity today. The share price has fallen dramatically from its 52-week high of HKD 16.28 to the current HKD 6.075, representing a 62.68% decline, with a year-to-date loss of 43.49%. Financial performance shows mixed signals: recent quarters reported revenue of approximately HKD 2.17 billion, up 18% year-over-year, indicating resilience in the core business; however, operating profit is negative at HKD 147 million loss, with earnings per share at negative HKD 0.3735. Recently, the company appointed CEO Jonathan W. Chen and its Endovastec subsidiary reported nine-month revenue of RMB 1.12 billion, up 10.26% year-over-year. Current market capitalization stands at approximately HKD 11.65 billion with a price-to-earnings ratio of 30.85x. The trading halt prevents price discovery, leaving investors without a market window.
News
PUBT · MicroPort Scientific subsidiary Endovastec reports nine-month revenue up 10.26% to RMB 1.12 billion
Global Report · Hong Kong Healthcare Stocks Split: Far Eastern Pharma's FDA Gamble vs. Real Estate Quagmire
Global Report · LQIDA's AI Edge Push Drives Hong Kong Small-Cap M&A Surge into Tech, Biotech
PUBT · MicroPort Scientific Files List of Board and Committee Members
PUBT · MicroPort Names Jonathan W. Chen CEO and Executive Director
Weekly Review · Weekly Recap | MICROPORT this week, halted all week
